Conventional Therapies that are being used with fewer side effects
There are a number of clinics that use a combination of alternative and conventional therapies. For a list of some of these clinics, go to our webpage devoted to this.
Low dose chemotherapy is being used by a number of clinics, including Revici, Rational , Klinik St George, Northern Health, Immune Institute, and more. The chemo can be targeted to a particular organ or administered in lower doses, thus side effects are reduced.
There is a company CellControl out of Munich that specialize in the diagnosis and therapy of tumor diseases. Their main product ChemoSelect® is an innovative chemosensitivity test procedure: Through tests performed on tissue samples, it permits predicting the on probable success of a particular chemotherapy before that therapy is even started. It helps determine an appropriate therapy for the individual patient. In addition, ThermoSelect® permits determining the effectiveness of hyperthermia in both, the presence or absence of cytostatics. You could have your doctor contact them. Their website is http://www.cellcontrol.de/english/index_e.html.
ST1 571, also known as Glivac is a cancer pill that is being used to treat chronic myelogenous leukemia (CML), and may be effective in treating certain types of brain, specifically glioblastoma, and stomach cancers, especially gastrointestinal stromal tumors, a rare cancer of the digestive system's connective tissue..
STI-571 is a part of a growing group of molecularly targeted treatments in which drugs are designed to treat diseases with specific genetic changes. It blocks a signal that the abnormal protein sends out, preventing the abnormal growth and production of other cancerous cells.
The drug STI-571 is now in clinical trials for glioblastoma, a kind of brain tumor, and for gastrointestinal stromal tumors and leukemia under a new agreement between the National Cancer Institute and Novartis Pharmaceuticals. Go to our clinical trials page to link to websites giving information on these trials, or go to http://www.cancer.gov/clinicaltrials/digestpage/gleevec.
The drug is scheduled to receive FDA approval soon.